Autologous Anti-CD19/CD20/CD22 CAR T-cells

Preferred Label : Autologous Anti-CD19/CD20/CD22 CAR T-cells;

NCIt synonyms : Autologous Anti-CD19/CD20/CD22 CAR-T Cells; Autologous CAR19.20.22 CAR T-cells; Autologous Anti-CD19/CD20/CD22 CAR T Cells;

NCIt definition : A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19), CD20 and CD22, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19/CD20/CD22 CAR T-cells target and bind to CD19, CD20 and CD22 expressed on the surface of certain tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. CD19, CD20 and CD22 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies.;

Détails

Origin ID

C213125;

chemical_or_drug_affects_cell_type_or_tissue
- Cytotoxic T-Lymphocyte [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Sensitization [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Immunopotentiation [NCIt concept]
- T-Cell Activation [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- B-Cell Receptor CD22 [NCIt concept]
- B-Lymphocyte Antigen CD19 [NCIt concept]
- B-Lymphocyte Antigen CD20 [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients